Mendoza, Yolanda Guerra http://orcid.org/0000-0002-4001-7662
Jusot, Viviane http://orcid.org/0000-0002-7747-8788
Adou, Félix
Ota, Martin http://orcid.org/0000-0002-1155-2842
Elenge, Diego Mpia http://orcid.org/0000-0002-2054-7287
Begum, Tasim http://orcid.org/0009-0008-0373-2860
Mdladla, Nkululeko http://orcid.org/0009-0000-0099-4365
Menang, Olga http://orcid.org/0000-0002-3928-4288
Yavo, Jean Claude http://orcid.org/0000-0001-6824-0674
Kamagaté, Mamadou http://orcid.org/0000-0002-5047-4840
Funding for this research was provided by:
GlaxoSmithKline Biologicals SA
Article History
Accepted: 10 October 2023
First Online: 15 November 2023
Change Date: 29 November 2023
Change Type: Update
Change Details: The original article has been corrected. Supplementary materials were missing from this article and have now been uploaded.
Declarations
:
: This work was supported by GlaxoSmithKline Biologicals SA. GlaxoSmithKline Biologicals SA provided financial support, including allowances for the dedicated PV coordinator and PV data manager, for training and mentoring HCPs, and for improvement of the national PV centre. GlaxoSmithKline Biologicals SA also covered the costs associated with the development and publishing of the present manuscript.
: YGM, VJ, MO, and DME are employees of GSK. YGM and DME hold shares in GSK. TB was an employee of GSK at the time of the study conduct. All other authors have no relevant financial conflict of interest to disclose. All authors have no non-financial conflict of interest to disclose.
: The minutes of meetings and discussions held with national pharmacovigilance stakeholders or health care professionals and other data that are not personally identifiable information are available from the corresponding author on reasonable request. Individual case safety reports are country owned and available on the World Health Organization database, VigiBase.
: Ethical approval was not required for this work.
: Not applicable.
: Not applicable.
: Not applicable.
: All authors contributed to the technical details and planning of the PV enhancement pilot project in Côte d’Ivoire. All authors reviewed and edited the manuscript. All authors read and approved the final manuscript. All authors have agreed to be personally accountable for their own contributions as well as for the accuracy and integrity of any part of the work.
: WhatsApp is a registered trademark of Meta Platforms Inc. Vigibase is a trademark of Uppsala Monitoring Centre.